What clinicians need to know about intranasal esketamine for treatment-resistant depression?

Judith D HopeDavid CopolovJohn TillerMegan GalballyMalcolm HopwoodJ Richard Newton Nicholas A Keks

Published in: Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists (2023)

Intranasal esketamine plus antidepressant has been approved by regulators as moderately effective and acceptably tolerable for treatment-resistant depression. Cost is a drawback. Use often needs to be long-term and vigilance for abuse is essential.

Keyphrases

depressive symptoms
sleep quality
major depressive disorder
palliative care
bipolar disorder
drug administration